Conference Proceedings

Polatuzumab vedotin obinutuzumab venetoclax in patients with relapsed/refractory (R/R) follicular lymphoma (FL): Primary analysis of a phase 1b/2 trial.

Rajat Bannerji, Sam Yuen, Tycel Jovelle Phillips, Christopher Arthur, Iris Isufi, Paula Marlton, John Francis Seymour, Paolo Corradini, Annalia Molinari, Giuseppe Gritti, Robert Emmons, Jamie Hirata, Lisa Musick, Sourish Saha, Brandon Croft, Christopher Flowers

Journal of Clinical Oncology | American Society of Clinical Oncology (ASCO) | Published : 2021

Abstract

7534 Background: Polatuzumab vedotin (Pola) + obinutuzumab (G) demonstrated activity and tolerability in a Phase 1b/2 trial of patients (pts) with R/R FL (Phillips, et al. Blood 2016). Preclinical studies with venetoclax (Ven) showed that concurrent treatment with Pola promotes MCL-1 degradation, a known mechanism of resistance to Ven, and enhances in vivo anti-tumor efficacy (Amin, et al. AACR 2020). Here, we report the primary safety/efficacy analysis with Pola-G-Ven in a Phase 1b/2 study of pts with R/R FL (GO29833; NCT02611323). Methods: Pts received induction treatment every 21 days (D) x six cycles (C) of: Pola 1.4–1.8mg/kg intravenously (IV) in dose escalation (DE) or recommended Pha..

View full abstract